CD25/IL-2R alpha Antibody (Hu102) [Biotin]
Novus Biologicals, part of Bio-Techne | Catalog # FAB9927B
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry
Label
Biotin
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Hu102
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human CD25/IL-2 R alpha
Specificity
Detects human CD25/IL-2 R alpha in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Daclizumab.
This product is for research
use only.
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for CD25/IL-2R alpha Antibody (Hu102) [Biotin]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD25/IL-2R alpha
Long Name
Interleukin 2 Receptor alpha
Alternate Names
CD25, IL-2 R alpha, IL-2Ra, IL2R alpha, IL2RA
Additional CD25/IL-2R alpha Products
Product Documents for CD25/IL-2R alpha Antibody (Hu102) [Biotin]
Product Specific Notices for CD25/IL-2R alpha Antibody (Hu102) [Biotin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...